These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24346637)

  • 1. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.
    Vourvahis M; Plotka A; Kantaridis C; Fang A; Heera J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):564-70. PubMed ID: 24346637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
    Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
    Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
    Guglieri-López B; Ventura-Cerdá JM; Gómez-Álvarez S; Climente-Martí M
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):331-6. PubMed ID: 25128462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS
    J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
    Mauss S; Böker K; Buggisch P; Christensen S; Hofmann WP; Schott E; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D
    Z Gastroenterol; 2015 Jul; 53(7):644-54. PubMed ID: 26167694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
    Gomes LO; Teixeira MR; Rosa JAD; Feltrin AA; Rodrigues JPV; Vecchi MD; Carneiro JMM; Noblat LACB; Chachá SGF; Martinelli ALC; Pereira LRL; Silveira MPT; Blatt CR; Farias MR
    Rev Inst Med Trop Sao Paulo; 2018; 60():e29. PubMed ID: 29972466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
    Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
    Wire MB; Fang L; Hussaini A; Kleha JF; Theodore D
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6704-9. PubMed ID: 25155600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
    Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
    Ramanathan S; Abel S; Tweedy S; West S; Hui J; Kearney BP
    J Acquir Immune Defic Syndr; 2010 Feb; 53(2):209-14. PubMed ID: 19851115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
    Kakuda TN; Abel S; Davis J; Hamlin J; Schöller-Gyüre M; Mack R; Ndongo N; Petit W; Ridgway C; Sekar V; Tweedy S; Hoetelmans RM
    Antimicrob Agents Chemother; 2011 May; 55(5):2290-6. PubMed ID: 21383098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.
    Chachá SGF; Rodrigues JPV; Araújo RC; Pereira LRL; Villanova MG; Souza FF; Santana RC; Martinelli ALC
    Rev Soc Bras Med Trop; 2018; 51(2):146-154. PubMed ID: 29768546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.